Market Newsdesk

ALLENTOWN, Pa., Dec. 1, 2020 /PRNewswire/ — PPL Corporation (NYSE: PPL) announced today that Joanne H. Raphael, executive vice president, general counsel and corporate secretary, plans to retire on June 1, 2021, after a 35-year career with the company.

“On behalf of PPL’s Board of Directors and our entire leadership team at PPL, I want to thank Joanne for her outstanding service and commitment to PPL,” said Vincent Sorgi, PPL president and chief executive officer.

“Throughout her distinguished career, Joanne has consistently provided exceptional leadership and counsel, expertly guiding legal, policy and communications strategies as PPL has grown and our industry has changed. She has been a tireless champion of diversity within PPL, a role model and mentor for so many employees, and a leader in our communities. And at all times, she has been someone who has served with passion and integrity in putting the best interests of our customers and shareowners first,” added Sorgi.

Raphael has served as PPL’s general counsel and corporate secretary since June 1, 2015. Prior to that, she held various roles within the legal department, including deputy general counsel. She was named to lead PPL’s External Affairs function in 1998, and over the years, she was responsible for federal and state government relations, corporate communications, environmental, real estate, community relations and economic development functions.

She serves as chair of the United Way of the Greater Lehigh Valley’s board of directors and is a director of the PPL Foundation, which contributes millions each year to improve the lives of individuals in the communities PPL serves.

The company said it will conduct an internal and external search to identify a successor. Raphael will assist to ensure a seamless transition to a new general counsel.

Headquartered in Allentown, Pa, PPL Corporation (NYSE: PPL) is one of the largest companies in the U.S. utility sector. PPL’s seven high-performing, award-winning utilities serve more than 10 million customers in the U.S. and United Kingdom. With more than 12,000 employees, the company is dedicated to providing exceptional customer service and reliability and delivering superior value for shareowners. To learn more, visit www.pplweb.com.

Note to Editors: Visit our media website at



www.pplnewsroom.com



 for additional news and background about PPL Corporation.

Contacts:  For news media: Ryan Hill, 610-774-4033
                  For financial analysts: Andy Ludwig, 610-774-3389

View original content to download multimedia:http://www.prnewswire.com/news-releases/ppl-general-counsel-to-retire-june-1-2021-301182549.html

SOURCE PPL Corporation

VANCOUVER, BC, Dec. 1, 2020 /PRNewswire/ – Callinex Mines Inc. (the “Company” or “Callinex”) (TSXV: CNX) (OTC: CLLXF) announces that its officers, directors and key personnel have exercised 176,666 stock options for total proceeds of $256,333.  Of $256,333 proceeds received, a total of $198,000 related to options with an exercise price of $3.30 per share.  By exercising stock options with an above market strike price, management and directors are demonstrating their firm belief in the intrinsic value across the Company’s exploration portfolio.

About Callinex Mines Inc.

Callinex Mines Inc. (TSXV: CNX) (OTC: CLLXF) is advancing its portfolio of base and precious metals rich deposits located in established Canadian mining jurisdictions. The portfolio is highlighted by the rapidly expanding Rainbow Discovery at its Pine Bay Project located near existing infrastructure in the Flin Flon Mining District. Additionally, Callinex has emerging near-surface silver discoveries at its Nash Creek Project located in the Bathurst Mining District of New Brunswick. A 2018 PEA on the Company’s Bathurst projects outlined a mine plan that generates a strong economic return with a pre-tax IRR of 34.1% (25.2% post-tax) and NPV8% of $230 million ($128 million post-tax).

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Some statements in this news release contain forward-looking information. These statements include, but are not limited to, statements with respect to future expenditures. These statements address future events and conditions and, as such, involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the statements. Such factors include, among others, the ability to complete the proposed drill program and the timing and amount of expenditures. Except as required under applicable securities laws, Callinex does not assume the obligation to update any forward-looking statement.

View original content:http://www.prnewswire.com/news-releases/callinex-announces-stock-option-exercise-301182557.html

SOURCE Callinex Mines Inc.

SOUTH SAN FRANCISCO, Calif., Dec. 1, 2020 /PRNewswire/ — VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders, today announced that Louis Monti, M.D., Ph.D., a pioneer in the research and development of neuroactive steroids known as “pherines,” including VistaGen’s intranasal drug candidates PH94B for anxiety disorders and PH10 for depression disorders, has joined the Company as Vice President, Translational Medicine.

“We have had the pleasure of working closely with Dr. Monti in a consultative capacity since 2018 to complement our efforts to develop PH94B and PH10 to improve the lives of millions of people worldwide who suffer from anxiety and depression disorders every day,” stated Shawn K. Singh, Chief Executive Officer of VistaGen. “As we approach several potentially significant milestones for these differentiated neuropsychiatric drug candidates in 2021 and beyond, Dr. Monti’s unique knowledge, expertise, and insight about their potential, as well as potential opportunities for further expansion of our CNS pipeline, will be valuable. We are excited that he has now joined us as a full-time member of our R&D team.”

Dr. Monti commented, “Driving research of neuroactive pherines to develop innovative medicines with the potential to lift the burdens of anxiety and depression has been a passion throughout my career. I am truly pleased to join a team that shares that sense of commitment and purpose. I am excited that my new role at VistaGen will allow me both to continue to assist with the late-stage clinical development of PH94B and PH10 and apply my R&D experience working with neuroactive steroids to explore potential pipeline expansion opportunities.”

Dr. Monti has served as President and CEO of Pherin Pharmaceuticals since July 2018. He previously served as its Executive Vice President between 2002 and 2018 and as its Vice President of Research from its founding in 1991 to 2002. Prior to joining Pherin, Dr. Monti held various academic positions at the University of Utah and the University of the Republic, Uruguay. He earned an M.D. from the University of the Republic, Uruguay School of Medicine, and a Ph.D. in Physiology and Pharmacology from the University of Utah. Dr. Monti holds memberships in the New York Academy of Sciences, the American Society of Clinical Psychopharmacology, and the International Brain Organization.

About PH94B
PH94B is an innovative odorless investigational synthetic neuroactive steroid nasal spray with therapeutic potential in multiple mental health disorders involving anxiety or phobia and is designed to have rapid onset. Self-administered in microgram-level doses, in Phase 2 studies for the treatment of social anxiety disorder (SAD), PH94B produced rapid-onset (within approximately 15 minutes) anti-anxiety effects without sedation or systemic uptake and distribution.

VistaGen is currently preparing PH94B for Phase 3 development as a potential acute treatment of anxiety in adults with SAD. The FDA has granted Fast Track designation for the development of PH94B for this indication.

With rapid-onset pharmacology and favorable safety results seen in all clinical studies to date, we believe PH94B has the potential to provide an innovative treatment alternative to benzodiazepines and other pharmacological alternatives in the acute drug treatment paradigm for SAD, as well as others anxiety disorders.

About PH10
PH10 is an innovative odorless investigational synthetic neuroactive nasal spray designed to have rapid onset and therapeutic potential in several neuropsychiatric indications involving depression and suicidal ideation. Following successfully completed exploratory Phase 2A clinical development, VistaGen is preparing for Phase 2B clinical development of PH10 as a potential stand-alone, rapid-onset treatment for major depressive disorder (MDD).

About VistaGen
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. Each of VistaGen’s three drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all clinical studies to date, and has therapeutic potential in multiple CNS markets. For more information, please visit www.vistagen.com and connect with VistaGen on Twitter, LinkedIn and Facebook.

Forward Looking Statements
Various statements in this release are “forward-looking statements” concerning VistaGen’s future expectations, plans and prospects, including the potential for successful clinical development and commercialization of PH94B for anxiety disorders and PH10 for depression disorders. These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties which could cause actual results to differ materially from those contemplated in these forward-looking statements, including the risks that: development and approval of PH94B and PH10 may not be achieved in any market; the FDA may decide that the results of the Company’s PH94B and PH10 clinical programs are not sufficient for regulatory approval for acute treatment of anxiety in adult patients with SAD or MDD, respectively, or any other anxiety- or depression-related disorder; development of PH94B and PH10 may not be successful in any indication; success in nonclinical studies or in earlier-stage clinical trials may not be repeated or observed in future studies, which may not support further development or be sufficient to gain regulatory approval to market PH94B or PH10; adverse events may be encountered at any stage of development that negatively impact further development. Other risks and uncertainties include, but are not limited to, issues related to: adverse healthcare reforms and changes of laws and regulations; general industry and market conditions; manufacturing and marketing risks, including risks related to the COVID-19 pandemic, which may include, but are not limited to, unavailability of or delays in delivery of raw materials for manufacture of PH94B or PH10; inadequate and/or untimely supply of PH94B or PH10 to meet demand; entry of competitive products; and other technical and unexpected hurdles in the development, manufacture and commercialization of PH94B and PH10, as well as those risks more fully discussed in the section entitled “Risk Factors” in VistaGen’s Annual Report on Form 10-K for the year ended March 31, 2020, and in its most recent Quarterly Report on Form 10-Q for the quarter and six months ended September 30, 2020, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s other filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent the Company’s views only as of today and should not be relied upon as representing its views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements.

View original content:http://www.prnewswire.com/news-releases/vistagen-therapeutics-expands-rd-team-with-appointment-of-louis-monti-md-phd-pioneer-in-the-development-of-neuroactive-steroids-known-as-pherines-as-potential-treatments-for-anxiety-and-depression-disorders-as-vice-presid-301182559.html

SOURCE VistaGen Therapeutics

NEW YORK, Dec. 1, 2020 /PRNewswire/ — InvestorsObserver issues critical PriceWatch Alerts for TTNP, MRNA, MBRX, CRBP, and ALT.

To see how InvestorsObserver’s proprietary scoring system rates these stocks, view the InvestorsObserver’s PriceWatch Alert by selecting the corresponding link.

• TTNP: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=TTNP&prnumber=120120201
• MRNA: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=MRNA&prnumber=120120201
• MBRX: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=MBRX&prnumber=120120201
• CRBP: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=CRBP&prnumber=120120201
• ALT: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=ALT&prnumber=120120201

(Note: You may have to copy this link into your browser then press the [ENTER] key.)

InvestorsObserver’s PriceWatch Alerts are based on our proprietary scoring methodology. Each stock is evaluated based on short-term technical, long-term technical and fundamental factors. Each of those scores is then combined into an overall score that determines a stock’s overall suitability for investment.

View original content to download multimedia:http://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-titan-pharmaceuticals-moderna-moleculin-biotech-corbus-pharmaceuticals-or-altimmune-301182574.html

SOURCE InvestorsObserver

ROCHESTER, N.Y., Dec. 1, 2020 /PRNewswire/ — The latest Paychex |IHS Markit Small Business Employment Watch shows that small business hiring remained largely consistent with the prior month, moderating slightly, down 0.03 percent nationally to 94.29. In November, hourly earnings growth stood at 2.76 percent, while weekly hours worked showed a decrease of 0.04 percent year over year.

“The Index has been essentially flat since August, showing no signs of immediate recovery,” said James Diffley, chief regional economist at IHS Markit.

“As the pandemic reaches yet another peak in the U.S., both employment and wage growth have remained relatively steady over the past quarter,” said Martin Mucci, Paychex president and CEO. “Despite the recent surge, small businesses across the U.S. continue to show resiliency, validating other key metrics we monitor that have been showing similar trends.”

The report also includes regional, state, metro, and industry level analysis, showing:

• The South remains the top-ranked region for employment growth, a full one point above the next highest region.
• The Northeast is the only region with weekly earnings growth above three percent.
• Texas has climbed one spot in the rankings each month for the past quarter, now ranking first among states in job growth.
• Construction leads all industries in job growth for the seventh consecutive month.
• Leisure and Hospitality lags with the weakest index for the past eight months.

The complete results for November, including interactive charts detailing all data at a national, regional, state, metro, and industry level, are available at www.paychex.com/employment-watch. Highlights are available below. 

Note: Data presented for the month of November was collected from Friday, October 16 through Thursday, November 19, the cutoff date for the Small Business Employment Watch.

National Jobs Index

• Since dropping below 95 in April, the national index has moderated between 94 and 95 for the past seven months.
• At 94.29, the Small Business Jobs Index slowed 0.03 percent in November and 3.89 percent from last year.
• The national index reached a new low for the second consecutive month.

National Wage Report

• Hourly earnings growth slowed for the fifth consecutive month, from a peak of 3.29 percent in June to 2.76 percent in November.
• At -0.04 percent in November, weekly hours worked growth turned negative for the first time since May; one-month and three-month annualized growth were both down more than one percent for the second consecutive month.
• Weekly earnings reported growth below three percent for the first time since September 2019.

Regional Jobs Index

• There was very little movement across the four major regions in November, as each edged down very slightly.
• At 95.62, the South remains the top-ranked region and is one point above the next highest region, the Midwest (94.62).
• The West remains the lowest-ranked region for the third consecutive month, reaching a new historic low for the fourth consecutive month.

Regional Wage Report 

• The Northeast is the only region with weekly earnings growth above three percent, though it has quickly slowed from a June peak of 7.35 percent.
• Earnings and hours worked growth is weakest in the South.
• Hourly earnings growth has slowed for 12 consecutive months in the West, from 3.41 percent last November to 2.63 percent this November.

State Jobs Index

• Texas gained 0.63 percent in November, moving ahead of Florida for the top-ranked state index at 96.73; Texas has climbed one spot in the rankings each month for the past quarter, gaining 1.01 percent.
• Though Washington is the weakest state index for the fifth straight month, it has improved 0.71 percent during the past quarter.
• Virginia fell 1.69 percent and in November, pulling its index down nine spots among states to 93.70.

Note: Analysis is provided for the 20 largest states based on U.S. population.

State Wage Report

• New Jersey, Massachusetts, and Pennsylvania lead hourly earnings growth among states, all above four percent, though one-month and three-month annualized growth rates are signaling a slowdown.
• Florida and Georgia have the weakest weekly hours worked growth among states, both down more than one percent year-over-year.
• With hourly earnings growth up one percent and weekly hours worked growth down one percent, weekly earnings growth in Texas is just 0.01 percent, last among states.

Note: Analysis is provided for the 20 largest states based on U.S. population.

Metropolitan Jobs Index 

• The gap in metro performance shrunk in November as top-ranked Denver declined 0.80 percent and lowest-ranked Seattle increased 1.05 percent.
• Dallas spiked 1.05 percent to 97.22, while Houston moderated -0.08 percent with an index level of 95.39.
• Baltimore recovered 1.15 percent this past month as its index is now down just 1.28 percent from last year.

Note: Analysis is provided for the 20 largest metro areas based on U.S. population.

Metropolitan Wage Report

• With hourly earnings growth of 5.88 percent, Riverside tops the metro rankings for the sixth straight month; Riverside weekly hours worked growth ranks second as well.
• Three metros have hourly earnings growth above four percent, while three metros have hourly earnings growth below two percent.
• Tampa remains in the middle of the pack for earnings and hours worked growth among metros, though one-month annualized growth for both dropped considerably in November, signaling weakening conditions.

Note: Analysis is provided for the 20 largest metro areas based on U.S. population.

Industry Jobs Index

• There was little change among industries in November; Construction leads all industries for the seventh consecutive month, while Leisure and Hospitality lags with the weakest index for the past eight months.
• Six of the eight industry sectors are above the national index level (94.29) as Manufacturing (92.73) and Leisure and Hospitality (88.14) are pulling down the national level of small business employment growth.

Note: Analysis is provided for seven major industry sectors. Definitions of each industry sector can be found here. The Other Services (excluding Public Administration) industry category includes religious, civic, and social organizations, as well as personal services, including automotive and household repair, salons, drycleaners, and other businesses.

Industry Wage Report 

• Leisure and Hospitality ranks first among sectors in hourly earnings growth (4.15 percent) and last in weekly hours worked growth (-2.44 percent).
• At 3.76 percent, Construction leads in weekly earnings growth among sectors and is the only sector with one-month and three-month growth above three percent.
• Unlike other sectors, Financial Activities did not experience a significant disruption in weekly hours worked as growth has been steadily positive and consistent during 2020.

Note: Analysis is provided for seven major industry sectors. Definitions of each industry sector can be found here. The Other Services (excluding Public Administration) industry category includes religious, civic, and social organizations, as well as personal services, including automotive and household repair, salons, drycleaners, and other businesses.

For more information about the Paychex | IHS Markit Small Business Employment Watch, visit www.paychex.com/employment-watch and sign up to receive monthly Employment Watch alerts.

*Information regarding the professions included in the industry data can be found at the Bureau of Labor Statistics website.

About the Paychex | IHS Markit Small Business Employment Watch

The Paychex | IHS Markit Small Business Employment Watch is released each month by Paychex, Inc., a leading provider of payroll, human resource, insurance, and benefits outsourcing solutions for small-to medium-sized businesses, and IHS Markit, a world leader in critical information, analytics, and expertise. Focused exclusively on small business, the monthly report offers analysis of national employment and wage trends, as well as examines regional, state, metro, and industry sector activity. Drawing from the payroll data of approximately 350,000 Paychex clients, this powerful tool delivers real-time insights into the small business trends driving the U.S. economy.

About Paychex
Paychex, Inc. (NASDAQ:PAYX) is a leading provider of integrated human capital management solutions for payroll, benefits, human resources, and insurance services. By combining its innovative software-as-a-service technology and mobility platform with dedicated, personal service, Paychex empowers small- and medium-sized business owners to focus on the growth and management of their business. Backed by more than 45 years of industry expertise, Paychex served more than 680,000 payroll clients as of May 31, 2020 across more than 100 locations in the U.S. and Europe, and pays one out of every 12 American private sector employees. Learn more about Paychex by visiting paychex.com and stay connected on Twitter and LinkedIn.

About IHS Markit (www.ihsmarkit.com)
IHS Markit (NYSE: INFO) is a world leader in critical information, analytics and solutions for the major industries and markets that drive economies worldwide. The company delivers next-generation information, analytics and solutions to customers in business, finance and government, improving their operational efficiency and providing deep insights that lead to well-informed, confident decisions. IHS Markit has more than 50,000 business and government customers, including 80 percent of the Fortune Global 500 and the world’s leading financial institutions. Headquartered in London, IHS Markit is committed to sustainable, profitable growth.

IHS Markit is a registered trademark of IHS Markit Ltd. and/or its affiliates. All other company and product names may be trademarks of their respective owners © 2020 IHS Markit Ltd. All rights reserved.

Media Contacts

Lisa Fleming

Paychex, Inc.
+1 585-387-6402
[email protected] 
@PaychexNews 

Kate Smith

IHS Markit
+1 781-301-9311
[email protected] 

Colleen Bennis

Mower
+1 585-389-1865
[email protected] 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/key-indicators-of-small-business-employment-show-stability-amid-recent-surge-in-covid-19-cases-across-the-us-301182577.html

SOURCE Paychex, Inc.

Key changes to the Exchange’s most popular go-public vehicle aimed at deal makers

TORONTO, Dec. 1, 2020 /CNW/ – TSX Venture Exchange (TSXV) today announced changes to its Capital Pool Company (CPC) program, following extensive consultation with stakeholders across the TSXV community. The CPC program is a unique listing vehicle exclusively offered by TSXV and accounted for almost 50% of new TSXV listings in the past 10 years.

New changes to the policy will take effect on January 1, 2021 and will provide:

• Increased flexibility – new jurisdictions added, residency restrictions eased, spending restrictions simplified
• Reduced regulatory burden – relaxed requirements on shareholder distribution and shareholder approval, fewer restrictions on PRO subscriptions
• Improved economics – increased seed investment, finders fees, shorter escrow

“The CPC program is a unique, innovative go-public vehicle tailored to serve the needs of growth companies in all sectors and is the leading source of new listings on TSX Venture Exchange. We are proud of the program’s long track record of success in expanding opportunities for companies to access public growth capital,” said Loui Anastasopoulos, President, Capital Formation, TMX Group. “As the Canadian financial landscape continues to evolve, we recognize the importance of working together with our clients and stakeholders to ensure the services and solutions we provide to enable success remain relevant. We thank our partners across the community for working with us to identify significant ways we can enhance the CPC program and make these important policy changes.”

Representatives from both the provincial and national advisory committees will join TMX executives to open the market this morning at 9:30 a.m. EST.

The CPC program provides an alternative, two-step introduction to the capital markets by introducing investors with financial market experience to entrepreneurs whose growth and development-stage companies require capital and public company management expertise.

Since its inception in 1986, there have been over 2,600 CPCs created and more than 2,200 qualifying transactions (QTs) completed. Former CPCs have raised over $75 billion in equity capital on TSX and TSXV. TSXV will be hosting virtual events on December 8 and 9, 2020 to review the key policy changes. For more information, please visit tsx.com/cpc.

For Market Openings:

 Media may pick up a feed from the TOC (television operations centre) for all market open ceremonies. The feed is named TSX Transmit 1 (SD-SDI) and is produced at the TMX Broadcast Centre and sent live to the TOC. To pick up the feed via the Dejero network, please contact [email protected]. The client feature video will begin playing on the TMX media wall at approximately 9:27 a.m. ET and the markets will open with the sound of a siren at 9:30 a.m. ET.

About TMX Group (TSX:X) 

TMX Group operates global markets, and builds digital communities and analytic solutions that facilitate the funding, growth and success of businesses, traders and investors. TMX Group’s key operations include Toronto Stock Exchange, TSX Venture Exchange, TSX Alpha Exchange, The Canadian Depository for Securities, Montréal Exchange, Canadian Derivatives Clearing Corporation, and Trayport which provide listing markets, trading markets, clearing facilities, depository services, technology solutions, data products and other services to the global financial community. TMX Group is headquartered in Toronto and operates offices across North America (Montréal, Calgary, Vancouver and New York), as well as in key international markets including London and Singapore. For more information about TMX Group, visit our website at www.tmx.com. Follow TMX Group on Twitter: @TMXGroup.

SOURCE TMX Group Limited

TORONTO, Dec. 1, 2020 /PRNewswire/ – Canntab Therapeutics Limited (CSE:PILL.CN) (OTCQB:CTABF) (FRA:TBF1.F) (the “Company” or “Canntab“), the leading innovator in cannabinoid and terpene blends in hard pill form for medical and therapeutic applications, is pleased to announce that it has completed its first delivery of two (2) of a total of five (5) SKU’s ordered by MediPharm Labs Corp.  (TSE:LABS.TO) (OTC:MEDIF).  Further to Canntab’s press release dated June 2, 2020, the Company confirms that the total purchase order is approximately $1.3 Million.  Canntab intends to complete and deliver the entire order by the end of 2020.

“Our first commercial production and delivery of this initial portion of our order from MediPharm Labs Corp. is a major milestone event for our company for three important reasons. First, this is evidence our science, quality assurance programs and production can be executed with the required standards to reflect our unique patented product of pressed tablets and caplets. Second, Canntab’s wide range of products will finally be available to all Canadians through a variety of retail and wholesale channels.  Finally, Canntab will be able to recognize revenue from its core product that will have a strong distribution base which will result in continuous sales through further expansion. Canntab will continue to enhance shareholder value by growing revenue through its domestic channels and expanding sales to international customers.” explains Larry Latowsky, Chief Executive Officer of Canntab.

About Canntab Therapeutics

Canntab Therapeutics is a Canadian biopharmaceutical company focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations.  Canntab’s proprietary hard pill cannabinoid formulations provide doctors, patients and consumers with medical grade solutions which incorporate all the features one would expect from any prescription or over the counter medication sold in Canadian pharmacies. These will include the following formulations: once a day and extended release, both providing an accurate dose and improved shelf stability.

Canntab holds a Cannabis Standard Processing & Sales for Medical Purposes Licence, a Cannabis Research Licence, and an Industrial Hemp Licence from Health Canada.

Canntab trades on the Canadian Securities Exchange under the symbol PILL, on the OTCQB under the symbol CTABF, and on the Frankfurt Stock Exchange under the symbol TBF1.

Cautionary Statements 

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Certain information in this press release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or negatives of these terms and similar expressions. Forward- looking statements are based on certain assumptions, including Canntab’s ability to fulfil the entire purchase order by the end of 2020, that the Company will continue to grow revenues through domestic channels and international expansion, and general business, economic, competitive, political and social uncertainties will not prevent the Company from conducting its business. While Canntab considers these assumptions to be reasonable, based on information currently available, they are inherently subject to significant business, economic and competitive uncertainties and contingencies and they may prove to be incorrect. Readers are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements also necessarily involve known and unknown risks, including without limitation, risks associated with delays in fulfilling MediPharm Labs Corp.’s purchase order, general economic conditions, adverse industry events, marketing costs, loss of markets, future legislative and regulatory developments, the inability to access sufficient capital on favourable terms, the medical and recreational cannabis industry in Canada and internationally in general, income tax and regulatory matters, the ability of Canntab to execute its business strategies, competition, crop failure, currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ from those anticipated. Forward-looking statements are not guarantees of future performance. Except as required by law, Canntab disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, events or otherwise. Forward- looking statements contained in this news release are expressly qualified by this cautionary statement.

View original content to download multimedia:http://www.prnewswire.com/news-releases/canntab-begins-delivery-of-tablets-to-medipharm-301182565.html

SOURCE Canntab Therapeutics Limited